Treatment with mAbs has a longer half-life than other anti-MM drugs in ongoing and completed clinical trials combining with lenalidomide/len and dexamethasone/dex with elotuzumab (elo) targeting CS1 (SLAMF7) [149], furthermore, daratuzumab (Dara) and SAR650984 (SAR) targeting CD38 [147, 150]. This evidence concerns the gene CD38 and Miyoshi myopathy.